MAIA enters into ATM agreement to sell up to $1.445M of common stock via H.C. Wainwright

MAIA Biotechnology, Inc.

ATM agreement with H.C. Wainwright to sell up to $1,445,000 of common stock.
Wainwright will receive 3.0% commission on gross proceeds from each sale.
Shares sold under existing effective shelf registration statement (Form S-3).
Agreement terminates upon sale of all shares or by either party at any time.
Company not obligated to sell any shares; may suspend solicitation at any time.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MAIA Biotechnology, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $1,445,000 (effective 2024-02-14).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: up to $1,445,000
Effective: 2024-02-14

Exact text from the filing

On February 14, 2024, MAIA Biotechnology, Inc. (“we,” “us,” the “Company” or “MAIA”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), to sell shares of our common stock, par value $0.0001 per share, (the “Shares”) having an aggregate sales price of up to $1,445,000

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-036587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.